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chondrocyte secreted proteins using the stable isotope labelling by amino
acids in cell culture (SILAC) technique.
Methods: Cartilage obtained from patients undergoing joint replacement,
or from patients with no history of joint disease was provided by the
Tissue Bank and the Autopsy Service at CHU A Coruña. The study was
approved by the local Ethics Committee. Chondrocytes released from car-
tilage by enzymatic digestion were recovered and plated at low density
in basic SILAC medium (Silantes) supplemented with antibiotics and 10%
FBS dialyzed. In the case of light media, standard L-lysine (146 mg/L) and
L-arginine (28 mg/L) were used, while in the heavy media isotope-labelled
L-lysine (13C6), and isotope-labelled L-arginine (13C6,15N4) were used. When
complete incorporation of the heavy isotope was achieved in the cells (2-3
weeks), normal (N) chondrocytes were treated with CS 200μg/mL and
then stimulated with IL-1β 5ng/mL, while osteoarthritic (OA) chondrocytes
were treated with CS 200μg/mL alone. 48 hours later, conditioned media
were collected and their proteins were concentrated and quantiﬁed. Heavy
and light samples were mixed 1:1, and 4 μg of each mixed sample
were in-solution reduced, alkylated and digested with trypsin. Separation
and analysis of the resulting tryptic peptide mixtures was performed by
nanoscale reversed-phase-LC-MS/MS. The identiﬁcation and quantiﬁcation
of proteins was carried out with Protein Pilot software, which detects the
heavy/light peak pairs and calculates the heavy/light ratios based on the
peak areas. Identiﬁcations with a probability score higher than 95% and
quantiﬁcations with a p value ≤0.05 were included in the results list.
Results: Database search (UniprotKB/Swissprot) allowed us the identiﬁca-
tion of 39 different proteins in the OA chondrocyte secretome and 70 in
N chondrocyte secretome. Interestingly, in both cases the most abundant
protein was cartilage glycoprotein 39, which has been previously related
with OA pathogenesis. For biological and functional analysis we considered
only those proteins detected in all replicates with a heavy/light ratio ≥1.2
or ≤0.8. In OA chondrocytes, chondroitin sulfate mainly improves the an-
abolic/catabolic balance of the extracellular cartilage matrix, by increasing
the level of structural proteins like collagens, decorin, lumican, vimentin
and ﬁbronectin. In N chondrocytes stimulated with IL1β, CS appears to
act primarily as an anti-inﬂammatory drug. We show in this work how
CS reduces inﬂammation by two mechanisms: directly, by decreasing the
presence of potent inﬂammatory mediators like IL6 (ratio=0.6), and also
indirectly, by increasing proteins such as tumor necrosis factor α-induced
protein (TSG6, ratio=3). TSG6 plays a crucial role in extracellular matrix
formation, inﬂammatory cell migration and cell proliferation. It’s a key
component of a negative feedback loop operating through the protease
network which reduces matrix degradation during OA process. The mech-
anism driven by TSG6 leads to a decrease in proMMPs activation, which
might protect cartilage from extensive degradation even in the presence of
acute inﬂammation (represented in our case by a high level of IL1β).
Conclusions: We have carried out the ﬁrst pharmacoproteomic study
using a quantitative proteomics approach (SILAC), based on the metabolic
labelling of the cells, to study the effect of CS on chondrocyte secretome.
Our ﬁndings provide novel information about the mechanisms that may
exert the in vivo beneﬁcial effects of CS on the OA disease process. This
work also illustrates that chondrocyte secreted proteins are an attractive
sub-proteome for the discovery of new targets of CS in OA therapy.
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Purpose: Previous in-house proteomic work identiﬁed several secreted
proteins from equine cartilage explants in response to recombinant
equine interleukin-1 beta (IL-1β) with or without the non-steroidal anti-
inﬂammatory drug, carprofen. The aim of this study was to validate the
presence of six of these proteins by western blotting. We also used quan-
titative densitometry to determine the effects of IL-1β, with or without
carprofen treatment, on levels of these proteins in the cartilage secretome
compared to control explants.
Methods: Cartilage explants were obtained from weight-bearing regions
of metacarpophalangeal joints of horses euthanized for purposes other
than for research. Explants were either incubated alone (control: C), with
IL-1β (10ng/ml), or in combination with IL-1β and carprofen (IL-1β+ CA,
10ng/ml and 100μg/ml respectively) at 37°C for 5 days. Culture medium
supernatants were collected and each sample divided into two aliquots.
One aliquot underwent tryptic digestion and high-throughput proteomic
analysis by ESI (Electrospray Ionisation) mass spectrometry using a Bruker
HCT PTM discovery ion trap instrument. Comparative proteomic analysis
of the supernatants identiﬁed a number of potentially relevant proteins.
The remaining corresponding aliquots were resolved on 1-D gels and
either silver stained to compare their electrophoretic proﬁles or used for
western blotting to validate protein expression. Six of the most commonly
identiﬁed proteins were selected for quantitative validation by western
blotting; cartilage oligomeric matrix protein (COMP), thrombospondin-1
(TSP-1), clusterin (mature and precursor forms), cartilage intermediate
layer protein-1 (CILP-1) and the matrix metalloproteinases MMP-1 and
MMP-3.
Results: SDS-PAGE and silver staining revealed qualitative differences
between the electrophoretic proﬁles of samples exposed to the different
treatments. Western blotting conﬁrmed the presence of COMP, TSP-1,
clusterin, clusterin precursor, CILP-1, MMP-1 and MMP-3 in explant su-
pernatants. Quantitative densitometry indicated that TSP-1, MMP-1 and
MMP-3 levels were increased in IL-1β and IL-1β+CA samples compared
to controls. Carprofen reduced MMP-1 and MMP-3 levels in IL-1β+CA
compared to IL-1β treatment alone. CILP-1 and clusterin levels remained
unchanged in all treatments, although the clusterin precursor was de-
creased in IL-1β samples.
Figure 1
Conclusions: The authors’ previous proteomic work has identiﬁed several
relevant extracellular matrix proteins in explant supernatants stimulated
with IL-1β. This study conﬁrmed the presence of six of these proteins
by quantitative western blotting and densitometry. Many of the identi-
ﬁed proteins have well-known matrix functions including participation
in cell-matrix and matrix-matrix interactions (i.e. TSP-1, COMP, CILP),
matrix turnover (MMP-1, MMP-3) and extracellular molecular chaperone
activity (clusterin). The validation described in this study suggests that
this high-throughput proteomic system provides a useful tool to identify
candidate proteins from the cartilage secretome for further quantitative
analysis using western blotting.
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Purpose: The aim of this study is to standardize the stable isotope labelling
by amino acids in human chondrocytes cell culture (SILAC) technique, and
to apply this novel strategy for the study of osteoarthritis (OA) patho-
physiology. To attain this objective, we have used an in vitro model of
inﬂammation based on the stimulation of human articular chondrocytes
with the cytokine Interleukin-1β (IL1β), a key OA mediator.
Methods: Cartilage obtained from patients with no history of joint disease
